INVA
Innoviva, Inc.
Biotechnology · Healthcare · United States
20.75
close · 2026-08-13
value
95
cheaper than peers95
quality
81
stronger fundamentals81
ranked against
Biotechnology (commercial)
value
quality
101 peerswide variation
Value inputs
| measure | company | vs peers |
| forward P/E | 9.39× | 92 |
| price to book | 1.22× | 90 |
| price to sales | 3.80× | 88 |
| EV to EBITDA | 6.90× | 76 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 50.7% | 93 |
| operating margin | 40.1% | 92 |
| debt to equity | 24.7% | 44 |
| revenue growth | 10.6% | 34 |
4 of 4 measures available
Facts
| market cap | $1B |
| free cash flow | $105.2M |
| employees | 159 |
| first trade | 2004-10-05 |
| next earnings | not reported |
| fundamentals updated | 2026-07-29 |